Prolactin and autoimmune diseases in humans.
Prolactin has been shown to have immunomodulatory as well as lactogenic effects. Generally less well known is that prolactin may also play a role in the activity of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Studies have shown decreasing prolactin production to be beneficial in animal models of autoimmune disease. Thus far, double-blinded, placebo-controlled studies of dopamine agonist treatment in humans with autoimmune disease have been done only in lupus patients, and support the potential efficacy of such agents. Small, open-label trials have also suggested potential benefit in patients with rheumatoid arthritis, Reiter's syndrome, and psoriasis. More studies are required to further delineate the mechanisms by which prolactin affects autoimmune disease activity, to determine in which specific diseases prolactin plays a significant role, and to test the efficacy of prolactin-lowering agents as therapy for such diseases.
Chuang
Ellie
E
Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA.
Molitch
Mark E
ME
D000634:Aminoquinolines / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D001327:Autoimmune Diseases / Q000097:blood / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology*; D001971:Bromocriptine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000077465:Cabergoline; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D010396:Penicillamine / Q000008:administration & dosage / Q000627:therapeutic use; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011388:Prolactin / Q000032:analysis / Q000502:physiology*; D051381:Rats; D011981:Receptors, Prolactin / Q000172:deficiency / Q000235:genetics / Q000502:physiology
D000634:Aminoquinolines; D018491:Dopamine Agonists; D004873:Ergolines; D007166:Immunosuppressive Agents; D011981:Receptors, Prolactin; D001971:Bromocriptine; C046650:quinagolide; D016572:Cyclosporine; D011388:Prolactin; D010396:Penicillamine; D000077465:Cabergoline; D011241:Prednisone